drugset
drugset / Trial / NCT05095649

Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib

NCT05095649 ↗

Phase 2 Unknown 15 enrolled Andalusian Public Foundation for Health Research in Seville
NaSingle-groupOpen-labelTreatment

Summary

Phase II clinical trial to assess the efficacy of donor regulatory enriched T cells in steroid-refractory chronic graft versus host disease patients who did not obtain complete remission under treatment with ruxolitinib

Timeline

Start
2022-03-24
Primary completion
2025-08-15
Completion
2026-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Regulatory T-cell enriched infusion Cell therapy 2e+06 cells/kg —

Indications

chronic graft versus host disease